Table 3.
Demographic and clinical characteristics and Ab titer of responders and non-responders to vaccination based on Ab titer
| Responders (n = 81) | Non-responders (n = 16) | p | |
|---|---|---|---|
| F, n (%) | 65 (80.2) | 9 (56.3) | 0.039* |
| Age, mean ± SD | 44.5 ± 12.5 | 43.6 ± 10.1 | 0.787 |
| Weight, kg ± SD | 66.3 ± 13.1 | 68.6 ± 17.4 | 0.556 |
| Any allergy | 17 (21.5) | 3 (20) | 0.895 |
| Any comorbidity | 23 (29.1) | 1 (6.7) | 0.064 |
| Disease duration, mean ± SD | 11.5 ± 9.3 | 16.5 ± 7.9 | 0.035* |
| RR, n (%) | 76 (93.8) | 16 (100) | 0.594 |
| Relapses in the past year, mean ± SD | 0.5 ± 0.7 | 0.4 ± 0.8 | 0.639 |
| EDSS, median (IQR) | 1.5 (1.0–2.0) | 3.0 (2.5–3.5) | 0.002* |
| Treated with DMTs, n (%) | 75 (92.6) | 16 (100) | 0.258 |
| High-efficacy DMTs, n (%) | 41 (50.6) | 15 (93.8) | 0.003* |
| AntiCD20, n (%) | 7 (9.6) | 14 (87.5) | < 0.001* |
| Duration of treatment with antiCD20, years, mean ± SD | 0.8 ± 0.7 | 3.3 ± 1.3 | < 0.001* |
| Follow-up (months), mean ± SD | 6.1 ± 0.8 | 6.0 ± 0.9 | 0.962 |
| Total Abs, mean ± SD | 1129 ± 122 | 2.6 ± 9.9 | < 0.001* |
| Lag between second dose and test, mean ± SD | 2.5 ± 1.3 | 1.8 ± 0.8 | 0.109 |
Legend: F, females; SD, standard deviation; BMI, body mass index; RR, relapsing-remitting; EDSS, Expanded Disability Status Scale; DMTs, disease-modifying therapies. * = statistically significant